logo
logo
Varex Imaging Corporation

Varex Imaging Corporation

NASDAQ•VREX
CEO: Mr. Sunny S. Sanyal
セクター: Healthcare
業種: Medical - Devices
上場日: 2017-01-23
Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. The company sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. It has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was incorporated in 2016 and is headquartered in Salt Lake City, Utah.
連絡先情報
1678 S. Pioneer Road, Salt Lake City, UT, 84104, United States
801-972-5000
www.vareximaging.com
時価総額
$565.91M
PER (TTM)
-8.3
29.9
配当利回り
--
52週高値
$14.57
52週安値
$6.76
52週レンジ
86%
順位54Top 78.1%
2.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$209.60M+0.00%
直近4四半期の推移

EPS

$0.06+0.00%
直近4四半期の推移

フリーCF

-$26.80M+0.00%
直近4四半期の推移

2026 Q1 決算ハイライト

主なハイライト

Revenue Increased 4.9% Net revenues reached 209.6 M USD for the quarter, showing a 9.8 M USD increase compared to prior period.
Return to Profitability Net income attributable to Varex was 2.3 M USD, successfully reversing the prior period's 0.3 M USD loss.
Industrial Segment Leads Growth Industrial revenues grew 17.4% to 64.8 M USD, driven primarily by increased sales of inspection products.
Operating Costs Reduced Total operating expenses decreased 5.1% to 54.4 M USD compared to the prior period due to lower SG&A.

リスク要因

Tariff and Trade Uncertainty Ongoing tariff policies and geopolitical tensions may negatively impact competitiveness, increase costs, and affect results.
Customer Concentration Risk Top customer accounted for 16% of revenue and 12% of receivables, posing significant concentration risk.
Prior Goodwill Impairment Medical unit recorded $93.9 M goodwill impairment charge in the prior quarter due to sustained stock price decreases.
Supply Chain Volatility Risk Reliance on sole-source suppliers for key components creates vulnerability to disruption and potential cost increases.

見通し

Refinance Senior Notes Expect to refinance Senior Secured Notes maturing in October 2027 during fiscal year 2026 to manage debt maturity.
R&D Investment Focus Maintain R&D spending at 8% to 10% of annual revenues to support long-term growth and product innovation.
New Equipment Commitment Entered commitment to purchase manufacturing equipment for approximately $7.3 M over a three-year term.
Credit Facility Availability Revolving Credit Facility remains undrawn with $154.8 M availability as of January 2, 2026, supporting liquidity.

同業比較

売上高 (TTM)

Varex Imaging CorporationVREX
$854.40M
+4.1%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

粗利益率 (最新四半期)

Bicycle Therapeutics plcBCYC
100.0%
+1705.8pp
Lexicon Pharmaceuticals, Inc.LXRX
99.9%
+4.0pp
ADC Therapeutics SAADCT
92.7%
-2.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
OMER$845.84M-6.557.3%103.2%
CGEM$720.14M-3.3-41.6%0.2%
AVNS$692.11M-1.5-58.2%12.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.5%
横ばい
4四半期純利益CAGR
-30.7%
収益性の低下
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月6日
|
EPS:-
|
売上高:-
財務レポート
財務データ
ニュース
全年度
  • Form 10-Q - Q1 2026

    会計期末: 2026年1月2日|提出日: 2026年2月10日|
    売上高: $209.60M+0.0%
    |
    EPS: $0.06+0.0%
    予想を下回る
  • Form 10-K - FY 2025

    会計期末: 2025年10月3日|提出日: 2025年11月18日|
    売上高: $844.60M+4.1%
    |
    EPS: $-1.70-45.3%
    予想を下回る
  • Form 10-Q - Q3 2025

    会計期末: 2025年7月4日|提出日: 2025年8月7日|
    売上高: $203.00M-2.9%
    |
    EPS: $-2.15-6386.5%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年4月4日|提出日: 2025年5月8日|
    売上高: $212.90M+3.2%
    |
    EPS: $0.17+394.2%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年1月3日|提出日: 2025年2月6日|
    売上高: $199.80M+5.2%
    |
    EPS: $-0.01-40.6%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年9月27日|提出日: 2024年11月19日|
    売上高: $811.00M-9.2%
    |
    EPS: $-1.17-197.5%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年6月28日|提出日: 2024年8月1日|
    売上高: $209.10M-9.9%
    |
    EPS: $0.03-85.1%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年3月29日|提出日: 2024年5月2日|
    売上高: $206.20M-9.6%
    |
    EPS: $0.03-65.6%
    予想を下回る